You are here
P&T February 2018
A proposed CMS rule promising to consider a federal default prescription drug benefit after 2019 has startled manufacturers, pharmacy benefit managers, P&T committees, and pharmacies alike. We consider the rationale and potential effects of such a rule.
The authors review the pathophysiology, etiology, screening, and diagnosis of osteoporosis; selected professional guidelines and recommendations; nonpharmacological management; pharmacological options; and the cost-effectiveness of those options.
Through a retrospective review, the authors found that a pharmacy-led medication reconciliation program in a community hospital decreased the number of significant, serious, and life-threatening medication reconciliation errors upon patient admission.
We review key sessions on Hodgkin’s lymphoma, diffuse large B-cell lymphoma, thromboembolism, hemophilia, sickle cell disease, and chronic lymphocytic leukemia.
Upcoming antibacterial agents in the pipeline appear promising, but it is difficult to predict their long-term durability. This article focuses on investigational agents that target resistant gram-negative organisms commonly found in the health care setting.
The absence of a drug–disease interaction alert leads to a child’s death
CMS considering pharmacy counter discounts for Part D drugs in the future
Approvals, new indications, regulatory activities, and more
Benznidazole for pediatric patients with Chagas disease; vestronidase alfa-vjbk (Mepsevii) for adults and children with mucopolysaccharidosis type VII; and hepatitis B vaccine (recombinant), adjuvanted (Heplisav-B), for the prevention of infection caused by all known subtypes of hepatitis B virus in adults
Betrixaban (Bevyxxa): a direct-acting oral anti-coagulant factor Xa inhibitor